June 19, 2020 10:41 pm | Updated 10:41 pm IST - HYDERABAD
Dr. Reddy's Laboratories on Friday said it has introduced Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga in the U.S. market.
Indicated for the treatment of metastatic castration-resistant prostate cancer, Zytiga brand and generic market had U.S. sales of around $454 million MAT for the 12 months ended March 2020, Dr.Reddy’s said citing IQVIA Health numbers. Zytiga (abiraterone acetate) is a trademark of Johnson & Johnson Corporation.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
